Skip to main
SBRA

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Sabra Health Care REIT is well-positioned for growth, with high projected internal growth driven by SHOP exposure in a market with rising demand and limited supply, and external growth opportunities at accretive pricing. The company's strong balance sheet and discounted FFO multiples also contribute to a positive outlook. However, rising costs and potential issues with operators could impact lease coverage ratios and performance, while the current pandemic may also have an adverse effect. The recent strategic transactions, loan repayment, and updated guidance bode well for the company's future performance and we reiterate our Market Outperform rating and raise our price target to $25.

Bears say

Sabra Health Care REIT is facing significant financial risks due to its high concentration in behavioral health facilities and its heavy reliance on non-profit tenants. Despite the recent repayment of a mortgage debt, the company's debt-to-EBITDA ratio remains high and its profitability may be negatively impacted by ongoing renegotiations with tenants and potential lease amendments. Additionally, the company's increased guidance for G&A expenses and FFO may suggest potential challenges in growing revenue and controlling expenses, causing concerns for long-term profitability.

SBRA has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Hold based on their latest research and market trends.

According to 9 analysts, SBRA has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.